Explore

Program Map

Start with a treatment, device, company, diagnosis, or trial ID. Each record keeps the source trail close to the claim.

161Main(26 active)

148Status checked

135Strong

320Backlog

More filters and sort (1 active)

Company-led only

5 records in Main database · 4 strong · 5 status checked

Compare	Program	Company / Sponsor	Type	Product	Modality	Stage	Status	Reliability	Evidence	Conf.	Population	Indications
Add	PEDMARK by Fennec Pharmaceuticals	Fennec Pharmaceuticals	Therapeutic	-	Small Molecule	Marketed	Marketed	Details checkedStrong evidence	regulatory · Priority 1	98%	PediatricCisplatin Ototoxicity	Cisplatin-Induced Hearing LossHearing Loss
Add	SENS-401 (Arazasetron) by Sensorion	Sensorion	Therapeutic	-	Small Molecule	Phase 2	Active	Details checkedStrong evidence	company · Priority 1	94%	AdultSudden / SSNHL+2	Hearing LossSensorineural Hearing Loss+2
Add	SPI-1005 by Sound Pharmaceuticals	Sound Pharmaceuticals	Therapeutic	-	Small Molecule	Phase 3	Active	Details checkedStrong evidence	trial · Priority 1	90%	AdultNoise-Induced+2	Hearing LossSensorineural Hearing Loss+3
Add	ACOU085 by Acousia Therapeutics	Acousia Therapeutics GmbH	Therapeutic	-	Small Molecule	Phase 2	Active	Details checkedStrong evidence	company · Priority 2	93%	AdultAge-Related+1	Hearing LossSensorineural Hearing Loss+2
Add	DB-020 by Regeneron and Decibel	Regeneron Pharmaceuticals	Therapeutic	-	Drug Delivery	Phase 1	Completed	Details checkedStatus confirmedHistorical/discontinued	publication · Priority 2	92%	AdultCisplatin Ototoxicity	Cisplatin-Induced Hearing LossHearing Loss